The dynamic changes of serum IgM and IgG against SARS‐CoV‐2 in patients with COVID‐19

Abstract

Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a worldwide pandemic since it emerged in December, 2019. Previous studies have reported rapid antibody response to SARS‐CoV‐2 with the first 2‐3 weeks after symptom onset. Here, we retrospectively described the dynamic changes of serum IgM and IgG specifically against SARS‐CoV‐2 in later weeks (mainly 4‐10 weeks) in 97 hospitalized patients with COVID‐19. We observed that serum IgM and IgG, especially in patients with moderate‐to‐high levels, declined significantly between week 4‐10 after illness onset. Notably, IgG levels in high percentage of patients (77.5%, 31/40) rapidly declined by half, from 212.5 (range, 163.7‐420.3) to 96.3 (range, 75.0‐133.4) AU/ml, within 1‐2 weeks in the second month and then sustained around 100 AU/ml until discharge from hospital. Significant reduction of IgM was also observed as SARS‐CoV‐2 nucleic acid converted to negative (p=0.002). In the recovery stage, serum IgG declined significantly (early vs. late recovery stage, n=16, p=0.003) with a median reduction of 50.0% (range, 3.7‐77.0%). Our results suggested the decline of IgM may be an indicator of virus clearance and recovery patients may have robust immunity against reinfection within at least 3 months after illness onset. Yet, the rapid reduction of IgG by half arises serious concerns on the robustness and sustainability of humoral immune response in the future period after discharge, which is crucial for immunity strategy and developing vaccine. This article is protected by copyright. All rights reserved.

Detection of serum KL-6 and SARS-CoV-2 antibody in patients with coronavirus disease 2019 and the diagnostic value in severe disease

“…In addition to a signi cant decrease in the level of the in ammatory factor CRP, KL-6, an indicator of pulmonary brosis, was also signi cantly reduced. In addition, all three antibodies speci c to SARS-CoV-2, IgA, IgM, and IgG, were very signi cantly down-regulated, consistent with the results reported in previous studies [14,26]. It is worth investigating whether recovered patients will have the same risk of infection as that of previously uninfected people when encountering the SARS-CoV-2 virus again [26].…”

Comparative study of a new commercial recombinant line assay and two immunoassays for detection of SARS-CoV-2 IgG antibodies in PCR-confirmed outpatients

“…It has been shown in several studies that SARS-CoV-2 antibody response appears earlier and is more pronounced in severely ill patients compared to less severe cases [11,12]. In addition, the kinetics of antibody decline may differ as recent studies suggest individual variation in antibody decline [13]. These factors may influence the test results of different serological assays and could not be systematically considered in our study since the severity of disease in the COVID-19 patients was not known apart from the fact that all patients were treated as outpatients.…”

Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina

“…In a breakthrough report, Ibarrondo et al described that SARS-CoV-2 IgG antibodies decayed early and rapidly after symptom onset in persons with mild disease [14]. Other studies confirmed that indeed there is a decay in IgG levels but at a slower rate and at later times than that reported by Ibarrondo et al [11, 15-21]. Although our understanding in the antibody dynamics is still incomplete, specific IgG levels appear to be maintained during 4-5 months, or even longer, if we consider our data from plasma non-donors, presented in figure 5A.…”